cv 3988 has been researched along with 1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, M; Kimura, J; Nomura, H; Oh-Ishi, S; Tsushima, S | 1 |
| Baenziger, JE; Bennett, SA; Carswell, CL; Harris, CS; Ryan, SD | 1 |
2 other study(ies) available for cv 3988 and 1-0-octadecyl 2-0-acetyl sn-glycero-3-phosphorylcholine
| Article | Year |
|---|---|
Characterization of the activity of a platelet activating factor antagonist, CV-3988.
Topics: Alprazolam; Animals; Autacoids; Blood Pressure; Capillary Permeability; Dose-Response Relationship, Drug; Male; Phospholipid Ethers; Platelet Activating Factor; Rabbits; Rats; Rats, Inbred Strains; Skin; Thiazoles | 1987 |
Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.
Topics: Animals; Apoptosis; Carbon; Caspases; Cell Line; Cerebellum; Gene Expression Regulation; Mice; Micelles; Neurons; Neuroprotective Agents; Neurotoxins; Phospholipid Ethers; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Signal Transduction | 2008 |